Friday, January 04, 2019 2:33:56 PM
Adding shares or waiting...
If I didnt own any shares ,I would have been buying alot anywhere from 2.00 to 1.25 in the past month.
If I already own alot and am looking for best bargains,and if it makes enough difference between buying at 1.80 versus buying at 1.50 ,the risk is that it might not drop to 1.50. odds are 50/50 in my view. This 1.75/1.85 area is a resistance shoulder zone. it could get hammered down in todays final hour. I might tend to wait for that move. we see it happen all the time. In the last downwave from 2.00 to 1.25. I was thinking it ought to hold at 1.75,it ought to hold at 1.50.It ought to hold at 1.35 . it ought to hold at 1.25. and I bought most of these steps along the way down.
This time,I personally will wait for more at 1.50. I'm ok if it doesnt go there.
whats a bargain these days of 20 cents, buying 1000 shares, 200 bucks?
Whats most important is to own enough shares to make it a worthy investment. Having a cost basis of 2 dollars is much better than what alot of people have.
If I didnt own any shares ,I would have been buying alot anywhere from 2.00 to 1.25 in the past month.
If I already own alot and am looking for best bargains,and if it makes enough difference between buying at 1.80 versus buying at 1.50 ,the risk is that it might not drop to 1.50. odds are 50/50 in my view. This 1.75/1.85 area is a resistance shoulder zone. it could get hammered down in todays final hour. I might tend to wait for that move. we see it happen all the time. In the last downwave from 2.00 to 1.25. I was thinking it ought to hold at 1.75,it ought to hold at 1.50.It ought to hold at 1.35 . it ought to hold at 1.25. and I bought most of these steps along the way down.
This time,I personally will wait for more at 1.50. I'm ok if it doesnt go there.
whats a bargain these days of 20 cents, buying 1000 shares, 200 bucks?
Whats most important is to own enough shares to make it a worthy investment. Having a cost basis of 2 dollars is much better than what alot of people have.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
